$-0.43 EPS Expected for Intellia Therapeutics Inc. (NTLA)
March 1, 2018 – By Adrian Erickson
Analysts expect Intellia Therapeutics Inc. (NASDAQ:NTLA) to report $-0.43 EPS on March, 13.They anticipate $0.12 EPS change or 38.71 % from last quarter’s $-0.31 EPS. After having $-0.44 EPS previously, Intellia Therapeutics Inc.’s analysts see -2.27 % EPS growth. The stock decreased 4.15% or $1.13 during the last trading session, reaching $26.1. About 1.02 million shares traded or 10.11% up from the average. Intellia Therapeutics Inc. (NASDAQ:NTLA) has declined 46.16% since March 1, 2017 and is downtrending. It has underperformed by 62.86% the S&P500.
Intellia Therapeutics Inc. (NASDAQ:NTLA) Ratings Coverage
Among 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intellia Therapeutics had 5 analyst reports since May 31, 2016 according to SRatingsIntel. The rating was upgraded by Jefferies on Friday, August 5 to “Buy”. The stock has “Outperform” rating by Credit Suisse on Tuesday, May 31. Wedbush initiated the stock with “Outperform” rating in Tuesday, May 31 report. On Tuesday, May 31 the stock rating was initiated by Jefferies with “Hold”. Leerink Swann upgraded Intellia Therapeutics Inc. (NASDAQ:NTLA) on Friday, August 5 to “Outperform” rating.
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company has market cap of $1.11 billion. The firm develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. It currently has negative earnings. The Company’s ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells.
More recent Intellia Therapeutics Inc. (NASDAQ:NTLA) news were published by: Globenewswire.com which released: “Intellia Therapeutics to Present at February Healthcare Investor Conferences” on January 31, 2018. Also Globenewswire.com published the news titled: “Intellia Therapeutics to Present at March Healthcare Investor Conferences” on February 28, 2018. Fool.com‘s news article titled: “Here’s What Pushed Intellia Therapeutics Inc. Up 33.7% in January” with publication date: February 08, 2018 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.